NCT06455514 Post-CA Neuroprotection With Magnesium
| NCT ID | NCT06455514 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | NYU Langone Health |
| Condition | Cardiac Arrest |
| Study Type | INTERVENTIONAL |
| Enrollment | 178 participants |
| Start Date | 2025-03-25 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 178 participants in total. It began in 2025-03-25 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.
Eligibility Criteria
Inclusion Criteria: * Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved \<2 hours prior to recruitment Exclusion Criteria: * Age \< 18 years or \> 85 years * Traumatic cardiac arrests * Unsustained ROSC (\<20 minutes) * Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC * Plan for withdrawal of life support within 72 hours of ROSC * Known pregnant women at the time of the cardiac arrest * Known prisoners at the time of the cardiac arrest * Subjects who have a medical o social condition that would make them inappropriate for the study based on the PI's or clinical team judgement.
Contact & Investigator
Sam Parnia
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06455514 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06455514 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06455514 currently recruiting?
Yes, NCT06455514 is actively recruiting participants. Contact the research team at resuscitationlab@nyulangone.org for enrollment information.
Where is the NCT06455514 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06455514 clinical trial?
NCT06455514 is sponsored by NYU Langone Health. The principal investigator is Sam Parnia at NYU Langone Health. The trial plans to enroll 178 participants.